The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $359,133 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The General Hospital Corporation Research Management Division (doing business as Massachusetts General Hospital) to generate new genetic tools for advancing tendon and musculoskeletal research. Specifically, the project aims to develop constitutive and inducible FLP alleles, FLP/CRE dual recombinase responsive alleles, and validate their efficiency and specificity using existing indicator or CRE/FLP lines. These intersectional genetic tools will enable more precise targeting of specific tendon cell populations for lineage tracing and functional analysis to improve understanding of tendon formation, homeostasis, and repair. The research is expected to advance the development of future tendon therapies and be widely applicable to the broader musculoskeletal research community.
Generated 3/4/25, 8:03 AM